IMA
NASDAQ HealthcareImageneBio, Inc. - Common Stock
Biotechnology
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
๐ Market Data
| Price | $5.66 |
|---|---|
| Volume | 109,691 |
| Market Cap | 63.31M |
| RSI (14-Day) | 41.4 |
| 200-Day MA | $8.31 |
| 50-Day MA | $5.77 |
| 52-Week High | $18.00 |
| 52-Week Low | $3.94 |
| Forward P/E | -1.68 |
| Price / Book | 0.48 |
๐ฏ Investment Strategy Scores
IMA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (96/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (1/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find IMA in your text
Paste any article, transcript, or post โ the tool will extract IMA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.